Gland Pharma Q3 Profit Jumps 28% on Strong US & Europe Sales

Introduction to Gland Pharma's Q3 Performance

Gland Pharma Ltd announced a significant financial uplift for the third quarter ending December 31, 2025, with a consolidated net profit increase of nearly 28%. The Hyderabad-based pharmaceutical company's strong performance was primarily fueled by robust sales in its core international markets, including the United States and Europe, signaling a positive turn after a period of operational challenges.

Detailed Financial Results

For the quarter, Gland Pharma reported a consolidated net profit of ₹261 crore, a substantial rise from the ₹205 crore recorded in the same period a year earlier. Revenue from operations also saw a healthy increase, climbing 22.5% to reach ₹1,695 crore. This growth was complemented by a 21% rise in Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA), indicating improved operational efficiency and profitability. The company's Trailing Twelve Months (TTM) Earnings Per Share (EPS) stood at ₹47.97, marking a 4.85% year-on-year growth.

Key Drivers of Growth

The impressive quarterly results were largely attributed to the company's strong performance in its key export markets. Sales in the United States, which account for over half of the company's total revenue, grew by 19%. The European market delivered an even more remarkable performance, with sales surging by 54%. This growth is particularly noteworthy as it comes at a time when some larger Indian pharmaceutical peers have reported declines in the U.S. market due to intense competition and pricing pressures.

The Cenexi Turnaround

A critical factor in this quarter's success was the operational recovery of its Cenexi unit, a European contract development and manufacturing organization (CDMO) based in France and Belgium. The unit had faced production disruptions through much of 2025. According to CEO Shyamakant Giri, Cenexi's strong revenue traction was a key contributor to the company's consolidated performance. This turnaround not only boosted European sales but also demonstrated the strategic value of the acquisition in strengthening Gland Pharma's global manufacturing footprint.

Market Position and Stock Performance

As of January 29, 2026, Gland Pharma's market capitalization stood at approximately ₹29,121 crore. The stock has shown volatility, with a 52-week high of ₹2,131.00 and a low of ₹1,277.80. The company's Price-to-Earnings (P/E) ratio is 36.85, which is considered reasonable and slightly below the sector P/E of 37.93. Promoter holding has remained stable at 51.83% as of the December 2025 quarter, indicating continued confidence from its core investors.

| Key Financial Metrics (as of Jan 2026) | |---|---| | Market Cap | ₹29,121 crore | | Net Profit (Q3 FY26) | ₹261 crore | | Revenue (Q3 FY26) | ₹1,695 crore | | TTM P/E Ratio | 36.85 | | TTM EPS | ₹47.97 | | 52-Week High/Low | ₹2,131.00 / ₹1,277.80 | | Promoter Holding | 51.83% |

Analyst Recommendations and Outlook

Analyst sentiment on Gland Pharma remains mixed. Out of 13 analysts providing recommendations, the consensus leans towards 'Hold'. This reflects a cautious optimism, balancing the company's strong quarterly performance against broader market valuations and potential future challenges. Community sentiment, however, appears overwhelmingly positive, with online forums showing a 100% 'Buy' rating.

Future Trajectory

Looking ahead, Gland Pharma's management expects stronger momentum in the second half of the fiscal year. This optimism is based on the anticipated recovery of the Cenexi unit and a pipeline of new product launches. The company's strategic focus on complex injectables, vertical integration, and expansion of its global CDMO capabilities positions it well for sustainable growth. Investors will be closely watching whether the company can maintain its growth trajectory and translate its operational recovery into long-term value creation.